Sarcoidosis complicating treatment with natalizumab for Crohn's disease
<p style="text-align:justify;"> Natalizumab is a humanised monoclonal antibody targeting the lymphocyte adhesion molecule a4 integrin, with proven efficacy in multiple sclerosis (MS) and Crohn's disease (CD). The development of sarcoidosis with extrapulmonary involvement is rep...
| Main Authors: | , , , |
|---|---|
| Format: | Journal article |
| Published: |
BMJ Publishing Group
2011
|
| _version_ | 1797069898528063488 |
|---|---|
| author | Parisinos, C Lees, C Wallace, W Satsangi, J |
| author_facet | Parisinos, C Lees, C Wallace, W Satsangi, J |
| author_sort | Parisinos, C |
| collection | OXFORD |
| description | <p style="text-align:justify;"> Natalizumab is a humanised monoclonal antibody targeting the lymphocyte adhesion molecule a4 integrin, with proven efficacy in multiple sclerosis (MS) and Crohn's disease (CD). The development of sarcoidosis with extrapulmonary involvement is reported in two patients with refractory CD who had received maintenance therapy with natalizumab. This complication has not been previously reported. It is hypothesised that the effect of natalizumab in altering lymphocyte mucosal trafficking may underlie the development of sarcoidosis in these patients. </p> |
| first_indexed | 2024-03-06T22:31:14Z |
| format | Journal article |
| id | oxford-uuid:5859c2df-9392-469e-940a-7250fee8027f |
| institution | University of Oxford |
| last_indexed | 2024-03-06T22:31:14Z |
| publishDate | 2011 |
| publisher | BMJ Publishing Group |
| record_format | dspace |
| spelling | oxford-uuid:5859c2df-9392-469e-940a-7250fee8027f2022-03-26T17:02:46ZSarcoidosis complicating treatment with natalizumab for Crohn's disease Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:5859c2df-9392-469e-940a-7250fee8027fSymplectic Elements at OxfordBMJ Publishing Group2011Parisinos, CLees, CWallace, WSatsangi, J <p style="text-align:justify;"> Natalizumab is a humanised monoclonal antibody targeting the lymphocyte adhesion molecule a4 integrin, with proven efficacy in multiple sclerosis (MS) and Crohn's disease (CD). The development of sarcoidosis with extrapulmonary involvement is reported in two patients with refractory CD who had received maintenance therapy with natalizumab. This complication has not been previously reported. It is hypothesised that the effect of natalizumab in altering lymphocyte mucosal trafficking may underlie the development of sarcoidosis in these patients. </p> |
| spellingShingle | Parisinos, C Lees, C Wallace, W Satsangi, J Sarcoidosis complicating treatment with natalizumab for Crohn's disease |
| title | Sarcoidosis complicating treatment with natalizumab for Crohn's disease |
| title_full | Sarcoidosis complicating treatment with natalizumab for Crohn's disease |
| title_fullStr | Sarcoidosis complicating treatment with natalizumab for Crohn's disease |
| title_full_unstemmed | Sarcoidosis complicating treatment with natalizumab for Crohn's disease |
| title_short | Sarcoidosis complicating treatment with natalizumab for Crohn's disease |
| title_sort | sarcoidosis complicating treatment with natalizumab for crohn s disease |
| work_keys_str_mv | AT parisinosc sarcoidosiscomplicatingtreatmentwithnatalizumabforcrohnsdisease AT leesc sarcoidosiscomplicatingtreatmentwithnatalizumabforcrohnsdisease AT wallacew sarcoidosiscomplicatingtreatmentwithnatalizumabforcrohnsdisease AT satsangij sarcoidosiscomplicatingtreatmentwithnatalizumabforcrohnsdisease |